Retatrutide vs Semaglutide

Overview

This comparison separates Retatrutide and Semaglutide for reference—not product selection.

Retatrutide: Investigational triple hormone receptor agonist studied in obesity and metabolic research.

Semaglutide: GLP-1 receptor agonist approved for type 2 diabetes and weight management; the most studied compound in its class.

Differences

• Retatrutide is discussed across GLP-1, GIP, and glucagon receptors.
• Semaglutide functions here as a GLP-1 reference—not an AXIOM catalogue item.

Mechanism

Retatrutide: Retatrutide works across three hormone pathways involved in metabolism — the GLP-1, GIP and glucagon receptors. The plain-English version is that it uses three…

Semaglutide: Semaglutide activates the GLP-1 receptor. In plain terms it extends and amplifies the signal your body normally sends after a meal: the stomach empties more slo…

Pharmacology

Retatrutide: Pharmacokinetic detail should be read from primary literature.

Semaglutide: Pharmacokinetic detail should be read from primary literature.

Research

Retatrutide: Metabolic & GLP-1 research: Clinical trials show 17.5% weight loss at 24 weeks and 24.2% at 48 weeks.

Semaglutide: Metabolic & GLP-1 research: FDA-approved for chronic weight management with average 15-20% body weight loss in clinical trials.

Summary

Distinction

• AXIOM does not provide dosing, administration, or protocol guidance.
• Catalogue links appear only where AXIOM lists a research-use product.
• Reference-only compounds remain comparison terms without implying availability.

References

• pubmed.ncbi.nlm.nih.gov/37366315/
• pubmed.ncbi.nlm.nih.gov/40609566/
• pubmed.ncbi.nlm.nih.gov/41090431/
• pubmed.ncbi.nlm.nih.gov/39019866/
• pubmed.ncbi.nlm.nih.gov/37385280/
• pubmed.ncbi.nlm.nih.gov/38858523/
• pubmed.ncbi.nlm.nih.gov/40305708/
• pubmed.ncbi.nlm.nih.gov/33567185/

Questions